Search
Glutamic acid
go.drugbank.com/drugs/DB00142ApprovedInvestigationalNutraceuticalA peptide that is a homopolymer of glutamic acid.
Mixtures: AMINOPLASMAL® B. BRAUN 10%, AMINOPLASMAL® B. BRAUN 10%Gadoteric acid
go.drugbank.com/drugs/DB09132ApprovedInvestigationaldue to a decreased tendency of gadolinium dechelation. … Gadoteric acid, commonly used in the salt form gadoterate meglumine, is a macrocyclic, ionic gadolinium-based contrast agent (GBCA).
Categories: Compounds used in a research, industrial, or household settingPI-0824
go.drugbank.com/drugs/DB05516InvestigationalPeptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824. … Pemphigus vulgaris (PV) is an autoimmune disease affecting approximately 40,000 people worldwide.
INNO-305
go.drugbank.com/drugs/DB06025InvestigationalThe vaccine is a polyvalent Wilms tumor gene 1 (WT1) peptide analog vaccine. … INNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission.
Bumetanide
go.drugbank.com/drugs/DB00887ApprovedInvestigationalBumetanide is a sulfamyl diuretic.
Categories: Increased Diuresis at Loop of HenleProducts: Burinex - Tab 2mgOlodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalA once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period … Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA).
Osemozotan
go.drugbank.com/drugs/DB05339ExperimentalMN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)
Cosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalCosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the
SAR445136
go.drugbank.com/drugs/DB17708InvestigationalSAR445136 is an investigational zinc finger nuclease gene-edited cell therapy.
V-SARS
go.drugbank.com/drugs/DB15812Investigational[COVID-19 convalescent plasma] is currently being acquired from recovered COVID-19 patients and used as prophylaxis for the virus. … This therapeutic concept was applied to the development of V-SARS, which heat inactivates the plasma, and packages it into a once-daily pill form.